Last updated on May 2019

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: ATOPIC DERMATITIS
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Have completed the final active treatment visit for an originating study eligible to enroll participants directly into study BREEZE-AD3 OR
  • Meet criteria for NCT03334396 or NCT03334422.

Exclusion Criteria:

  • Had investigational product permanently discontinued at any time during a previous baricitinib study.
  • Had temporary investigational product interruption continue at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the participant's participation in the study.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.